{"contentid": 488698, "importid": NaN, "name": "Objective responses for Astellas and Seagen\u00e2\u0080\u0099s Padcev/Keytruda combo in urothelial cancer", "introduction": "Japan\u00e2\u0080\u0099s Astellas Pharma and US biotech Seagen have announced updated results from two clinical trials examining Padcev (enfortumab vedotin-ejfv) alone (EV-201 Cohort 2) and Padcev in combination with Merck & Co\u00e2\u0080\u0099s Keytruda (pembrolizumab) (EV-103 Cohort A) in patients with locally advanced or metastatic urothelial cancer who are not able to receive cisplatin chemotherapy.", "content": "<p>Japan&rsquo;s Astellas Pharma (TYO: 4503) and US biotech Seagen (Nasdaq: SGEN) have announced updated results from two clinical trials examining Padcev (enfortumab vedotin-ejfv) alone (EV-201 Cohort 2) and Padcev in combination with Merck &amp; Co&rsquo;s Keytruda (pembrolizumab) (EV-103 Cohort A) in patients with locally advanced or metastatic urothelial cancer who are not able to receive cisplatin chemotherapy.</p>\n<p>&ldquo;EV-201 Cohort 2 is the first study to report objective responses in patients with advanced urothelial cancer that progressed following immunotherapy and who have medical conditions that prevent them from receiving cisplatin chemotherapy,&rdquo; said Dr Andrew Krivoshik, senior vice president and Oncology Therapeutic Area Head, Astellas. &ldquo;The analysis that will be presented at ASCO showed that after a median follow-up of 16 months, many patients continued to benefit from Padcev &ndash; an important finding for these patients, who have very limited treatment options,&rdquo; he added.</p>\n<p>&ldquo;EV-103 is the first clinical trial to combine the antibody-drug conjugate Padcev with Merck&rsquo;s anti-PD-1 therapy Keytruda in patients newly diagnosed with locally-advanced or metastatic urothelial cancer,&rdquo; said Dr Roger Dansey, chief medical officer, Seagen. &ldquo;The updated data from EV-103 Cohort A, with two years of follow-up, build upon findings from the initial analysis, showing continued durability for this platinum-free combination,&rdquo; he noted.</p>\n<p>The US Food and Drug Administration recently granted Priority Review to a supplemental application for Padcev based on the primary analysis from EV-201 Cohort 2, which was published this month in <a href=\"https://doi.org/10.1016/S1470-2045(21)00094-2\"><em>The Lancet Oncology</em></a>.</p>\n<p>The FDA granted Breakthrough Therapy designation last year for the Padcev and Keytruda combination for patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy in the first-line setting.</p>", "date": "2021-05-21 14:25:00", "meta_title": "Objective responses for Astellas and Seagen\u00e2\u0080\u0099s Padcev/Keytruda combo in", "meta_keywords": "Astellas, Seagen, Merck & Co, Padcev, Keytruda, Combination, Trial, Cancer, Urothelial", "meta_description": "Objective responses for Astellas and Seagen\u00e2\u0080\u0099s Padcev/Keytruda combo in urothelial cancer", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-21 14:24:37", "updated": "2021-05-21 14:32:15", "access": NaN, "url": "https://www.thepharmaletter.com/article/objective-responses-for-astellas-and-seagen-s-padcev-keytruda-combo-in-urothelial-cancer", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "astellas-location-big.jpg", "image2id": "astellas-location-small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": "Metastatic urothelial cancer", "sector_tag": "Biotechnology", "therapy area_tag": "Immuno-oncology, Oncology", "topic_tag": "Asia Pacific, Drug Trial, Focus On, Research", "geography_tag": "Japan, USA", "company_tag": "Astellas, Merck & Co, Seagen", "drug_tag": "Keytruda, Padcev", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-21 14:25:00"}